147 related articles for article (PubMed ID: 9745778)
1. The effect of live measles vaccines on serum vitamin A levels in healthy children.
Yalçin SS; Yurdakök K; Ozalp I; Coşkun T
Acta Paediatr Jpn; 1998 Aug; 40(4):345-9. PubMed ID: 9745778
[TBL] [Abstract][Full Text] [Related]
2. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
Samoĭlovich EO; Kapustik LA; Fel'dman EV; Ermolovich MA; Svirchevskaia EIu; Titov LP; Zakharenko DF; Belova EIu; Chernovetskiĭ MA; Korostik TS
Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):36-40. PubMed ID: 9783398
[TBL] [Abstract][Full Text] [Related]
3. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
4. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
Usonis V; Bakasenas V; Kaufhold A; Chitour K; Clemens R
Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
[TBL] [Abstract][Full Text] [Related]
5. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.
Boulianne N; De Serres G; Ratnam S; Ward BJ; Joly JR; Duval B
Vaccine; 1995 Nov; 13(16):1611-6. PubMed ID: 8578850
[TBL] [Abstract][Full Text] [Related]
6. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
Cilla G; Peña B; Marimón JM; Pérez-Trallero E
Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
Miller E; Hill A; Morgan-Capner P; Forsey T; Rush M
Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
Just M; Berger R; Just V
Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
[TBL] [Abstract][Full Text] [Related]
9. Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months.
Forleo-Neto E; Carvalho ES; Fuentes IC; Precivale MS; Forleo LH; Farhat CK
Vaccine; 1997 Dec; 15(17-18):1898-901. PubMed ID: 9413099
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
Klinge J; Lugauer S; Korn K; Heininger U; Stehr K
Vaccine; 2000 Jul; 18(27):3134-40. PubMed ID: 10856793
[TBL] [Abstract][Full Text] [Related]
11. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.
White CJ; Stinson D; Staehle B; Cho I; Matthews H; Ngai A; Keller P; Eiden J; Kuter B
Clin Infect Dis; 1997 May; 24(5):925-31. PubMed ID: 9142794
[TBL] [Abstract][Full Text] [Related]
12. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
[TBL] [Abstract][Full Text] [Related]
13. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
[TBL] [Abstract][Full Text] [Related]
14. Response to measles-mumps-rubella vaccine in children on dialysis.
Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
[TBL] [Abstract][Full Text] [Related]
15. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine.
André FE; Peetermans J
Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
[TBL] [Abstract][Full Text] [Related]
18. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
[TBL] [Abstract][Full Text] [Related]
19. The combination measles, mumps, rubella and varicella vaccine in healthy children.
Arbeter AM; Baker L; Starr SE; Plotkin SA
Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
[TBL] [Abstract][Full Text] [Related]
20. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies.
Lindberg B; Ahlfors K; Carlsson A; Ericsson UB; Landin-Olsson M; Lernmark A; Ludvigsson J; Sundkvist G; Ivarsson SA
Pediatrics; 1999 Jul; 104(1):e12. PubMed ID: 10390298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
